Long-term Safety Profile of Dupilumab in Adults with Moderate to Severe Atopic DermatitisLong-term dupilumab use shows low infection rates in skin conditions

This observational, open-label extension study evaluated the long-term safety and tolerability of dupilumab in a large cohort of 2,677 adults diagnosed with moderate-to-severe atopic dermatitis (AD). The primary objective was to monitor the incidence of infections over an extended period of up to 260 weeks. Patients received dupilumab at dosages of 300 mg either weekly or every two weeks, providing clinicians with a robust dataset regarding long-term maintenance therapy.

The study specifically focused on various categories of infection, including overall infections, serious infections, and severe infections. These metrics are critical for healthcare providers when managing patients with chronic inflammatory skin conditions who may be at risk due to frequent use of topical corticosteroids or other systemic treatments. The data provides a comprehensive look at how the medication performs over several years rather than just months.

Results indicated that the incidence of overall infections was 70.69 per 100 person-years (PY). While this number may appear high, it is essential to contextualize these figures within the specific patient population and the duration of treatment. Serious infections were recorded at a rate of 0.87 per 100 PY, while severe infections occurred at a rate of 0.92 per 100 PY. These figures suggest that serious complications remain relatively low despite long-term exposure to the biologic.

Furthermore, the study tracked infections leading to treatment discontinuation, which were recorded at 0.34 per 100 PY. This metric is particularly useful for clinicians assessing the practical feasibility of dupilumab as a long-term maintenance therapy. The data suggests that most patients can remain on the medication without being forced to stop due to infection complications.

Several limitations were noted in the study design, including the absence of a concurrent placebo arm during the open-label extension phase and a decreasing sample size at later time points. Additionally, some analyses included weekly dosing, which differs from the standard approved every-two-week regimen. The potential confounding effects of concomitant topical corticosteroid use also warrant consideration when interpreting infection rates.

In conclusion, the data supports the safety of dupilumab for long-term management of moderate-to-severe atopic dermatitis in adults. For clinicians, these findings provide reassurance that extended treatment does not appear to significantly increase the risk of serious infections compared to expected baseline risks in this patient population.